Trial Profile
A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Status changed from recruiting to completed.
- 03 Mar 2022 Planned End Date changed from 1 Jul 2023 to 1 Sep 2025.
- 03 Mar 2022 Planned primary completion date changed from 1 Jul 2023 to 1 Sep 2025.